Intellia Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO

John M. Leonard

CEOJohn M. Leonard

Employees

526

Employees526

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

526

Employees526

NTLA Key Statistics

Market cap

2.27B

Market cap2.27B

Price-Earnings ratio

-4.36

Price-Earnings ratio-4.36

Dividend yield

—

Dividend yield—

Average volume

1.19M

Average volume1.19M

High today

$24.99

High today$24.99

Low today

$23.42

Low today$23.42

Open price

$24.44

Open price$24.44

Volume

1.29M

Volume1.29M

52 Week high

$47.48

52 Week high$47.48

52 Week low

$19.37

52 Week low$19.37

NTLA News

Yahoo Finance 3d

Why Intellia Therapeutics, Inc. Outpaced the Stock Market Today - Yahoo Finance

The most recent trading session ended with Intellia Therapeutics, Inc. (NTLA) standing at $23.60, reflecting a +1.42% shift from the previouse trading day's clo...

Yahoo Finance 4d

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates - Yahoo Finance

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing...

TipRanks 7d

Intellia Therapeutics to present updated data from Phase 1/2 study of NTLA-2002

Intellia Therapeutics announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy...

Analyst ratings

79%

of 28 ratings

Buy

78.6%

Hold

21.4%

Sell